{
    "clinical_study": {
        "@rank": "21946", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die. Combining more than one drug may kill more tumor cells.\n\n      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating\n      patients who have metastatic Ewing's sarcoma or primitive neuroectodermal tumor."
        }, 
        "brief_title": "Chemotherapy in Treating Patients With Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor", 
        "condition": "Sarcoma", 
        "condition_browse": {
            "mesh_term": [
                "Neuroectodermal Tumors", 
                "Neuroectodermal Tumors, Primitive", 
                "Sarcoma, Ewing's", 
                "Sarcoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the activity of cisplatin and etoposide in terms of response of patients with\n           metastatic Ewing's sarcoma or primitive neuroectodermal tumor.\n\n        -  Assess the bone marrow and kidney toxicity of this regimen in these patients.\n\n      OUTLINE: This is a multicenter study.\n\n      Patients receive cisplatin IV over 3 hours on days 1, 8, 15, 29, 36, and 43 and oral\n      etoposide daily on days 1-15 and 29-43 in the absence of disease progression or unacceptable\n      toxicity.\n\n      PROJECTED ACCRUAL: A total of 21-45 patients will be accrued for this study within 2 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed Ewing's family tumor as characterized by the following:\n\n               -  Positive MIC2 on immunohistochemistry OR\n\n               -  Evidence of a chromosomal translocation involving the EWS gene by conventional\n                  cytogenetics\n\n                    -  t(11; 22) translocation or variant OR\n\n                    -  Demonstration of EWS/FLI1 or EWS/ERG gene fusion by PCR or FISH\n\n          -  Metastases outside the lung or pleura\n\n          -  At least 1 measurable lesion outside of previously irradiated area\n\n          -  No symptomatic or known CNS metastases\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  15 to 65\n\n        Performance status:\n\n          -  WHO 0-2\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  WBC at least 3,000/mm3\n\n          -  Neutrophil count at least 2,000/mm3\n\n          -  Platelet count at least 100,000/mm3\n\n        Hepatic:\n\n          -  Bilirubin less than 3 mg/dL\n\n          -  Albumin greater than 2.5 g/dL\n\n        Renal:\n\n          -  Creatinine less than 1.2 mg/dL\n\n          -  Creatinine clearance greater than 70 mL/min\n\n        Cardiovascular:\n\n          -  No history of uncontrolled cardiovascular disease\n\n        Other:\n\n          -  No other severe medical illness, including psychosis\n\n          -  No other prior primary malignancy except adequately treated carcinoma in situ of the\n             cervix or basal cell skin cancer\n\n          -  Fertile patients must use effective contraception\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Not specified\n\n        Chemotherapy:\n\n          -  No prior chemotherapy\n\n        Endocrine therapy:\n\n          -  Not specified\n\n        Radiotherapy:\n\n          -  See Disease Characteristics\n\n        Surgery:\n\n          -  Not specified"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "15 Years"
        }, 
        "enrollment": {
            "#text": "3", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 10, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00014313", 
            "org_study_id": "EORTC-62993", 
            "secondary_id": "EORTC-62993"
        }, 
        "intervention": [
            {
                "intervention_name": "cisplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "etoposide", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Etoposide phosphate", 
                "Cisplatin", 
                "Etoposide"
            ]
        }, 
        "keyword": "metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor", 
        "lastchanged_date": "September 20, 2012", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/EORTC-62993"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Sutton", 
                    "country": "United Kingdom", 
                    "state": "England", 
                    "zip": "SM2 5NG"
                }, 
                "name": "Institute of Cancer Research - UK"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "official_title": "A Phase II Study to Evaluate the Role of Weekly Cisplatin With Oral Etoposide in Ewing's Sarcoma and Primitive Neuroectodermal Tumor (PNET) With Bone and/or Bone Marrow Metatstatic Disease", 
        "overall_official": {
            "affiliation": "Institute of Cancer Research, United Kingdom", 
            "last_name": "Ian R. Judson, MA, MD, FRCP", 
            "role": "Study Chair"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2002", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00014313"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "European Organisation for Research and Treatment of Cancer - EORTC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "European Organisation for Research and Treatment of Cancer - EORTC", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2001", 
        "study_design": "Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012", 
        "why_stopped": "low accrual"
    }, 
    "geocoordinates": {
        "Institute of Cancer Research - UK": "51.361 -0.194"
    }
}